Literature DB >> 16861629

Bacillus anthracis spores stimulate cytokine and chemokine innate immune responses in human alveolar macrophages through multiple mitogen-activated protein kinase pathways.

Kaushik Chakrabarty1, Wenxin Wu, J Leland Booth, Elizabeth S Duggan, K Mark Coggeshall, Jordan P Metcalf.   

Abstract

Contact with the human alveolar macrophage plays a key role in the innate immune response to Bacillus anthracis spores. Because there is a significant delay between the initial contact of the spore with the host and clinical evidence of disease, there appears to be temporary containment of the pathogen by the innate immune system. Therefore, the early macrophage response to Bacillus anthracis exposure is important in understanding the pathogenesis of this disease. In this paper, we studied the initial events after exposure to spores, beginning with the rapid internalization of spores by the macrophages. Spore exposure rapidly activated the mitogen-activated protein kinase signaling pathways extracellular signal-regulated kinase, c-Jun-NH2-terminal kinase, and p38. This was followed by the transcriptional activation of cytokine and primarily monocyte chemokine genes as determined by RNase protection assays. Transcriptional induction is reflected at the translational level, as interleukin-1alpha (IL-1alpha), IL-1beta, IL-6, and tumor necrosis factor alpha (TNF-alpha) cytokine protein levels were markedly elevated as determined by enzyme-linked immunosorbent assay. Induction of IL-6 and TNF-alpha, and, to a lesser extent, IL-1alpha and IL-1beta, was partially inhibited by the blockade of individual mitogen-activated protein kinases, while the complete inhibition of cytokine induction was achieved when multiple signaling pathway inhibitors were used. Taken together, these data clearly show activation of the innate immune system in human alveolar macrophages by Bacillus anthracis spores. The data also show that multiple signaling pathways are involved in this cytokine response. This report is the first comprehensive examination of this process in primary human alveolar macrophages.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16861629      PMCID: PMC1539616          DOI: 10.1128/IAI.00446-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody.

Authors:  S Welkos; A Friedlander; S Weeks; S Little; I Mendelson
Journal:  J Med Microbiol       Date:  2002-10       Impact factor: 2.472

2.  c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.

Authors:  Z Han; D L Boyle; L Chang; B Bennett; M Karin; L Yang; A M Manning; G S Firestein
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

3.  Lung macrophage-epithelial cell interactions amplify particle-mediated cytokine release.

Authors:  Florence Tao; Lester Kobzik
Journal:  Am J Respir Cell Mol Biol       Date:  2002-04       Impact factor: 6.914

4.  Early Bacillus anthracis-macrophage interactions: intracellular survival survival and escape.

Authors:  T C Dixon; A A Fadl; T M Koehler; J A Swanson; P C Hanna
Journal:  Cell Microbiol       Date:  2000-12       Impact factor: 3.715

5.  Fate of germinated Bacillus anthracis spores in primary murine macrophages.

Authors:  C Guidi-Rontani; M Levy; H Ohayon; M Mock
Journal:  Mol Microbiol       Date:  2001-11       Impact factor: 3.501

6.  Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis.

Authors:  Katherine C Brittingham; Gordon Ruthel; Rekha G Panchal; Claudette L Fuller; Wilson J Ribot; Timothy A Hoover; Howard A Young; Arthur O Anderson; Sina Bavari
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

Review 7.  Inhalational anthrax: epidemiology, diagnosis, and management.

Authors:  S Shafazand; R Doyle; S Ruoss; A Weinacker; T A Raffin
Journal:  Chest       Date:  1999-11       Impact factor: 9.410

8.  Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition.

Authors:  Jin Mo Park; Florian R Greten; Zhi-Wei Li; Michael Karin
Journal:  Science       Date:  2002-08-29       Impact factor: 47.728

9.  The history of anthrax.

Authors:  George Sternbach
Journal:  J Emerg Med       Date:  2003-05       Impact factor: 1.484

Review 10.  The alveolar macrophage: the Trojan horse of Bacillus anthracis.

Authors:  Chantal Guidi-Rontani
Journal:  Trends Microbiol       Date:  2002-09       Impact factor: 17.079

View more
  21 in total

1.  Gene expression profiling of primary human type I alveolar epithelial cells exposed to Bacillus anthracis spores reveals induction of neutrophil and monocyte chemokines.

Authors:  J Leland Booth; Elizabeth S Duggan; Vineet I Patel; Wenxin Wu; Dennis M Burian; David C Hutchings; Vicky L White; K Mark Coggeshall; Mikhail G Dozmorov; Jordan P Metcalf
Journal:  Microb Pathog       Date:  2018-04-25       Impact factor: 3.738

2.  Sporulation in mycobacteria.

Authors:  Jaydip Ghosh; Pontus Larsson; Bhupender Singh; B M Fredrik Pettersson; Nurul M Islam; Sailendra Nath Sarkar; Santanu Dasgupta; Leif A Kirsebom
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-16       Impact factor: 11.205

3.  Bacillus anthracis spore movement does not require a carrier cell and is not affected by lethal toxin in human lung models.

Authors:  J Leland Booth; Elizabeth S Duggan; Vineet I Patel; Marybeth Langer; Wenxin Wu; Armin Braun; K Mark Coggeshall; Jordan P Metcalf
Journal:  Microbes Infect       Date:  2016-06-16       Impact factor: 2.700

4.  Bacillus anthracis lethal toxin reduces human alveolar epithelial barrier function.

Authors:  Marybeth Langer; Elizabeth Stewart Duggan; John Leland Booth; Vineet Indrajit Patel; Ryan A Zander; Robert Silasi-Mansat; Vijay Ramani; Tibor Zoltan Veres; Frauke Prenzler; Katherina Sewald; Daniel M Williams; Kenneth Mark Coggeshall; Shanjana Awasthi; Florea Lupu; Dennis Burian; Jimmy Dale Ballard; Armin Braun; Jordan Patrick Metcalf
Journal:  Infect Immun       Date:  2012-10-01       Impact factor: 3.441

5.  Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.

Authors:  Crystal L Loving; Taruna Khurana; Manuel Osorio; Gloria M Lee; Vanessa K Kelly; Scott Stibitz; Tod J Merkel
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

6.  Human lung innate immune cytokine response to adenovirus type 7.

Authors:  Wenxin Wu; J Leland Booth; Elizabeth S Duggan; Krupa B Patel; K Mark Coggeshall; Jordan P Metcalf
Journal:  J Gen Virol       Date:  2010-01-13       Impact factor: 3.891

7.  Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms.

Authors:  Susan L Fink; Tessa Bergsbaken; Brad T Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-12       Impact factor: 11.205

8.  Resistance of human alveolar macrophages to Bacillus anthracis lethal toxin.

Authors:  Wenxin Wu; Harshini Mehta; Kaushik Chakrabarty; J Leland Booth; Elizabeth S Duggan; Krupa B Patel; Jimmy D Ballard; K Mark Coggeshall; Jordan P Metcalf
Journal:  J Immunol       Date:  2009-10-07       Impact factor: 5.422

9.  Bacillus anthracis capsule activates caspase-1 and induces interleukin-1beta release from differentiated THP-1 and human monocyte-derived dendritic cells.

Authors:  Min-Hee Cho; Hae-Jeong Ahn; Hyun-Joon Ha; Jungchan Park; Jeong-Hoon Chun; Bong-Su Kim; Hee-Bok Oh; Gi-Eun Rhie
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

10.  Gene expression profiling of human alveolar macrophages infected by B. anthracis spores demonstrates TNF-alpha and NF-kappab are key components of the innate immune response to the pathogen.

Authors:  Mikhail Dozmorov; Wenxin Wu; Kaushik Chakrabarty; J Leland Booth; Robert E Hurst; K Mark Coggeshall; Jordan P Metcalf
Journal:  BMC Infect Dis       Date:  2009-09-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.